• Evorel 25 is marked 'CE25', has a surface area of 8 sq cm and contains 1.6 mg estradiol corresponding to a release rate of 25 micrograms of estradiol in 24 hours. Patients should be told to contact their doctors immediately when they are aware of a potential thrombo-embolic symptom (eg, painful swelling of a leg, sudden pain in the chest, dyspnoea).There is no evidence from randomised controlled trials of protection against myocardial infarction in women with or without existing CAD who received combined oestrogen-progestagen or oestrogen- only HRT.Oestrogen-only: Randomised controlled data found no increased risk of CAD in hysterectomised women using oestrogen-only therapy.Combined oestrogen-progestogen therapy: The relative risk of CAD during use of combined oestrogen-progestogen HRT is slightly increased. Your doctor may decide to change the size of patch.The levels of hormone from the patches are too low to act as a contraceptive. If you're already using Evorel Conti patches, you can reorder them using Superdrug's Online Doctor service. Continue typing to refine. The displayed frequency categories use the following convention:Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data).Pain, Application site erythema*, Application site oedema*, Application site reaction* Additional adverse drug reactions reported in clinical trials of Evorel (estradiol only)The table below reports additional undesirable effects that have been reported in users of other hormone replacement therapy (HRT) by MedDRA system organ classes (MedDRA SOCs).Other adverse reactions have been reported in association with oestrogen/progestogen treatment: In the total hip, the increase in BMD was 2.17 ± 2.33 % with Evorel 50 and 2.82±0.51 % with Evorel 100. An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined oestrogen-progestagen therapy for more than 5 years.Results of the largest randomised placebo-controlled trial (WHI-study) and largest epidemiological study (MWS) are presented below:Additional cases per 1000 never-users of HRT over a 5 year period*2Additional cases per 1000 HRT users over 5 years (95% CI)*2 Taken from baseline incidence rates in developed countries.Note: since the background incidence of breast cancer differs by EU country, the number of additional cases of breast cancer differs by EU country; the number of additional cases of breast cancer will also change proportionately.Incidence per 1000 women in placebo arm over 5 yearsAdditional cases per 1000 HRT users over 5 years (95% CI)*3 WHI study in women with no uterus, which did not show an increase of breast cancer.In women with an intact uterus, the risk of endometrial hyperplasia and endometrial cancer increases with increasing duration of use of unopposed oestrogens. This includes medicines that you buy without a prescription or herbal medicines.Taking these medicines with Evorel can stop it from working as well. After stopping treatment, the risk may remain elevated for at least 10 years. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms.Oestrogens prevent bone loss following menopause or ovariectomy.Relief of menopausal symptoms was achieved to a similar degree during the first few weeks of treatment with Evorel 50 and Evorel 100.Oestrogen deficiency at menopause is associated with increasing bone turnover and decline in bone mass. They are clear with a sticky backing that can be stuck to the skin. Studies in animals have not shown reproductive toxicity.The results of most epidemiological studies to date relevant to inadvertent fetal exposure to combinations of oestrogens (and progestogens) indicate no teratogenic or foetotoxic effect.In normal use, Evorel would not be expected to have any effect on the ability to drive or use machinery.The safety of Evorel was evaluated in 2584 subjects who participated in 15 clinical trials and received at least one administration of Evorel. HRT may add to this risk. Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only or combined oestrogen-progestogen HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.